Understanding how genetic factors influence heart toxicity from cancer treatments
Elucidating Genetic Susceptibility of Covalent Kinase Inhibitors with iPSC "Cell Village"
This study is looking at how certain genes might make some cancer patients more likely to have heart issues from the cancer drug ibrutinib, so we can find out who might be at risk and help manage their treatment better.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10935740 on NIH RePORTER |
What this research studies
This research investigates how certain genetic traits may make cancer patients more susceptible to heart toxicity caused by a specific cancer drug called ibrutinib. By using advanced techniques to create patient-derived stem cells, researchers will study the effects of this drug on heart cells at a detailed level. The goal is to identify genetic markers that could predict which patients are at risk for heart problems after treatment, ultimately leading to better management strategies for those affected. Patients who have experienced heart toxicity from ibrutinib will be compared to those who have not to uncover these genetic insights.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who have been treated with ibrutinib and have either developed or not developed heart toxicity.
Not a fit: Patients who have not been treated with ibrutinib or those without cardiovascular concerns may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to personalized treatment plans that minimize heart toxicity in cancer patients receiving ibrutinib.
How similar studies have performed: Previous research has shown promise in understanding genetic susceptibility to drug toxicity, suggesting that this approach could yield valuable insights.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Wu, Joseph C. — Stanford University
- Study coordinator: Wu, Joseph C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.